Basmajian J V, Shankardass K, Russell D, Yucel V
Arch Phys Med Rehabil. 1984 Nov;65(11):698-701.
A minor tranquilizer, ketazolam, was tested in a double-blind, randomized, crossover study of 50 patients for its effects in neurologic spasticity. The drug was compared with diazepam (widely accepted as an effective antispasticity agent) and a placebo. The patients with spasticity were almost all cases of multiple sclerosis (24) or stroke (24). Thirty-nine patients completed the study. There was not statistically significant superiority of either diazepam or ketazolam, but both relieved symptoms significantly better than the placebo, as measured clinically and by electromyographic recording of deep tendon reflexes. Ketazolam is a relatively safe and clinically effective antispasticity agent (especially for patients with multiple sclerosis). The well-known "big 3"--dantrolene sodium, baclofen, and diazepam--produce large and small problems in many individual cases; hence, ketazolam now offers a safe and clinically useful alternative.
一种轻度镇静剂——氯唑仑，在一项针对50名患者的双盲、随机、交叉研究中，对其治疗神经痉挛的效果进行了测试。该药物与地西泮（被广泛认为是一种有效的抗痉挛药物）和安慰剂进行了比较。痉挛患者几乎都是多发性硬化症患者（24例）或中风患者（24例）。39名患者完成了研究。地西泮或氯唑仑在统计学上均无显著优势，但两者在临床测量和通过深部腱反射的肌电图记录方面，缓解症状的效果均明显优于安慰剂。氯唑仑是一种相对安全且临床有效的抗痉挛药物（尤其适用于多发性硬化症患者）。著名的“三大药物”——丹曲林钠、巴氯芬和地西泮——在许多个体病例中会产生大大小小的问题；因此，氯唑仑现在提供了一种安全且临床有用的替代药物。
